abbvie glp-1 receptor agonists weight management diabetes treatments Clinical of Regain and Cardiometabolic Consequences After Discontinuation of GLP‐1 - Shah - 2026 - Diabetes, Obesity and Metabolism Upcoming wave of hormone-based therapies

Description

[DOI] [PMC free article] [PubMed] [Google Scholar] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article.

Explore the potential of GLP-1 supplements in supporting wellness and metabolic health management

Michigan BCBS implemented what amounted to a near-complete removal of weight loss indication coverage, with narrow exceptions for members who could demonstrate specific comorbidities beyond obesity alone

Resistance training two to three times per week and 1.01.2 g/kg of daily protein are not optional they are part of the treatment

Eli Lilly delivered a Q1 2026 trifectaearnings beat, raised full-year guidance, and early-April FDA approval of Foundayo, the first oral GLP-1 with no food or water restrictionswidening its lead over Novo Nordisk just as the race for a convenient weight-loss pill heats up